DEVELOPMENT OF LIPIDIC DRUG DELIVERY SYSTEM FOR BIOAVAILABILITY IMPROVEMENT OF THE POORLY WATER SOLUBLE ANTI-HYPERTENSIVE DRUG
Main Article Content
Keywords
Drug, Oral, Delivery, Solubility, Lipid, Bioavailability.
Abstract
most medications used to treat different conditions are taken orally and supplied using a conventional delivery method. Oral dosing has a limited bioavailability due to its weak water solubility, chemical stability, and pre-systemic metabolism. Poorly water-soluble pharmaceuticals present a challenge to formulation specialists in terms of solubility and bioavailability. Lipid-based medication delivery systems are one of the new technologies developed to address these problems (LBDDS). Encapsulating or solubilizing the medication in lipid excipients can promote solubilization and absorption while also increasing bioavailability. In this study, we aim to investigate the various novel delivery techniques developed for improving the oral bioavailability of medications with low water solubility as well as the significance of solid lipid nanoparticles in the pharmacokinetics of such drugs. If carefully studied, solid lipid nanoparticles may offer fresh options for the treatment of hypertension with improved oral administration.
Downloads
References
[1]. Food and Drug Administration. (2000). Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD. [2]. Broccatelli, F., Cruciani, G., Benet, L. Z., &Oprea, T. I. BDDCS class prediction for new molecular entities. Molecular pharmaceutics, 2012; 9(3):570-580. [3]. Dudhipala N. Influence of Solid Lipid Nanoparticles on Pharmaco-dynamic Activity of Poorly Oral Bioavailable Drugs. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 Jul 11; 13(4):4979-83. [4]. Yum SI, Schoenhard G, Tipton AJ, Gibson JW, Middleton JC, inventors; Durect Corp, assignee. Oral drug delivery system. United States patent US 8,133,507. 2012 Mar 13. [5]. Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005). Global burden of hypertension: analysis of worldwide data. The lancet, 365(9455), 217-223. [6]. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Himmelfarb, C. D., ... & MacLaughlin, E. J. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 71(19), e127-e248. [7]. Palem, C. R., Gannu, R., Doodipala, N., Yamsani, V. V., &Yamsani, M. R. (2011). Transmucosal delivery of domperidone from bilayered buccal patches: in vitro, ex vivo and in vivo characterization. Archives of pharmacal research, 34(10), 1701-1710. [8]. Narendar, D., Arjun, N., Someshwar, K., & Rao, Y. M. (2016). Quality by design approach for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets for improved oral bioavailability. Journal of Pharmaceutical Investigation, 46(3), 253-263. [9]. Dudhipala, N. (2015). Enhancement of Solubility and Dissolution Rate of Trandolapril Sustained Release Matrix Tablets by Liquisolid Compact Approach. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 9(4). [10]. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov2007;6:231–48. [11]. Nekkanti V, Sandeep K. (2012) “Development of novel lipid based drug delivery system for raloxifene hydrochloride”. Int Res J Pharm; 3:166–73. [12]. Driscoll CMO. (2002) Lipid based formulations for intestinal lymphatic delivery. Eur J Pharm Sci;15:405–15. [13]. van den Bosch H, Postema NM, de Haas GH, van Deenen L. On the positional specificity of phospholipase A from pancreas. BiochimBiophys Acta 1965; 98:657–9. [14]. Erlanson-Albertsson C. Pancreatic colipase. Structural and physiological aspects. BiochimBiophys Acta 1992;1125:1–7. [15]. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277:3–9 16. Harde, H., Das, M., & Jain, S. (2011). Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert opinion on drug delivery, 8(11), 1407-1424. [17]. Narendar, D., & Kishan, V. (2017). Candesartan cilexetil nanoparticles for improved oral bioavailability. Ther deli, 8(2), 79-88. [18]. Dudhipala, N., Janga, K. Y., &Gorre, T. (2018). Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomedicine, and biotechnology, 1-10. [19]. Zhang, Z., Gao, F., Bu, H., Xiao, J., & Li, Y. (2012). Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine: Nanotechnology, Biology and Medicine, 8(5), 740-747. [20]. Sandeep, V., Narendar, D., Arjun, N., &Kishan, V. Lacidipine Loaded Solid Lipid Nanoparticles for Oral Delivery: Preparation, Characterization and In vivo Evaluation. [21]. Venishetty, V. K., Chede, R., Komuravelli, R., Adepu, L., Sistla, R., & Diwan, P. V. (2012). Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids and Surfaces B: Biointerfaces, 95, 1-9.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.